Systematic Review
Published on 15 Jan 2024
Bibliometric analysis of photodynamic therapy and immune response from 1989–2023
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1299253
- 1,604 views
- 1 citation
Type at least 3 characters
2,597 articles
Articles
Systematic Review
Published on 15 Jan 2024
The adverse events of CDK4/6 inhibitors for HR+/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1269922
- 3,491 views
- 4 citations
Case Report
Published on 15 Jan 2024
Positive outcomes with neoadjuvant chemotherapy in the management of colovesical fistula in cancer: a case report and literature review
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1284316
- 996 views
Original Research
Published on 12 Jan 2024
Deciphering hepatocellular carcinoma pathogenesis and therapeutics: a study on anoikis, ceRNA regulatory network and traditional Chinese medicine
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1325992
- 1,758 views
- 2 citations
Review
Published on 12 Jan 2024
Sexual dimorphism in bladder cancer: a review of etiology, biology, diagnosis, and outcomes
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1326627
- 1,900 views
- 1 citation
Review
Published on 11 Jan 2024
New sights of immunometabolism and agent progress in colitis associated colorectal cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1303913
- 2,042 views
- 1 citation
Review
Published on 11 Jan 2024
Ferroptosis: a dual-edged sword in tumour growth
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1330910
- 1,643 views
- 3 citations
Review
Published on 10 Jan 2024
The role of extracellular vesicles in cholangiocarcinoma tumor microenvironment
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1336685
- 1,615 views
- 2 citations
Review
Published on 10 Jan 2024
Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1340401
- 3,421 views
- 5 citations
Original Research
Published on 10 Jan 2024
Targeting p53 misfolding conundrum by stabilizing agents and their analogs in breast cancer therapy: a comprehensive computational analysis
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1333447
- 2,298 views
- 2 citations
Review
Published on 10 Jan 2024
Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1349081
- 7,631 views
- 6 citations
Systematic Review
Published on 09 Jan 2024
Destabilizing the genome as a therapeutic strategy to enhance response to immune checkpoint blockade: a systematic review of clinical trials evidence from solid and hematological tumors
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1280591
- 1,695 views
- 1 citation
Original Research
Published on 09 Jan 2024
Cyclohexene oxide CA, a derivative of zeylenone, exhibits anti-cancer activity in glioblastoma by inducing G0/G1 phase arrest through interference with EZH2
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1326245
- 1,639 views
Correction
Published on 09 Jan 2024
Corrigendum: A combination of metformin and epigallocatechin gallate potentiates glioma chemotherapy in vivo
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1322332
- 991 views
Mini Review
Published on 09 Jan 2024
Repurposing beta-blockers for combinatory cancer treatment: effects on conventional and immune therapies
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1325050
- 2,624 views
- 1 citation
Systematic Review
Published on 09 Jan 2024
Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1238579
- 1,672 views